In addition to their antiangiogenic activity, inhibitors of the vascular endothelial growth factor (VEGF) pathway enhance the anti-cancer activity of ICIs by blocking tumor-induced immune-suppressive cells and increasing T-cell infiltration into tumors (22–24). Here, VEGFA is linked to cancer.